- Esperion to Participate in Upcoming June Investor Conferences
- First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
- Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
- Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Esperion Reports First Quarter 2024 Financial Results
- Esperion to Participate in Upcoming May Investor Conferences
- Esperion to Report First Quarter 2024 Financial Results on May 7
- Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
- Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
More ▼
Key statistics
On Tuesday, Esperion Therapeutics Inc (0ET:BER) closed at 2.02, -36.39% below its 52-week high of 3.17, set on Apr 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.05 |
---|---|
High | 2.06 |
Low | 1.98 |
Bid | 1.99 |
Offer | 2.16 |
Previous close | 2.01 |
Average volume | 1.57k |
---|---|
Shares outstanding | 189.46m |
Free float | 188.47m |
P/E (TTM) | -- |
Market cap | 409.23m USD |
EPS (TTM) | -1.00 USD |
Data delayed at least 15 minutes, as of Jun 04 2024 19:08 BST.
More ▼